Christian Ledesma
Alicante, VC, Spain
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications
Low prevalence of bacterial coinfection at hospital admission in COVID-19 and the role of procalcitonin as a rule-out biomarker (Revised Version).
Journal: International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
Published: April 02, 2026
Antiviral therapy and interleukin-6 blockade associated with lower thrombotic risk in hospitalized COVID-19: a target trial emulation.
Journal: Scientific reports
Published: March 28, 2026
Impact of Gluteal Injection Site on Pharmacokinetics and Tolerability of Antiretroviral Therapy with Long-Acting Cabotegravir and Rilpivirine.
Journal: AIDS patient care and STDs
Published: November 17, 2025
Point-of-care ultrasound guidance for long-acting cabotegravir-rilpivirine administration improves injection-site tolerability and preserves pharmacokinetics.
Journal: AIDS (London, England)
Published: September 14, 2025
Virological Success With Long-Acting Cabotegravir and Rilpivirine Despite Historical Rilpivirine Resistance: A Real-World Case Series.
Journal: Open forum infectious diseases
Published: July 28, 2025
Influence of patient characteristics and oral lead-in on long-acting cabotegravir and rilpivirine pharmacokinetics and outcomes in people with HIV: a real-world study.
Journal: Antimicrobial agents and chemotherapy
Published: June 05, 2025
A decade of anal cancer screening in the context of HIV care.
Journal: AIDS (London, England)
Published: March 28, 2025
ADAR1 mRNA quantification for predicting HSIL in persons with HIV and abnormal anal cytology.
Journal: International journal of cancer
Published: February 22, 2025
Insights on Drug Levels and Non-Sustained Viral Suppression With Long-Acting Cabotegravir and Rilpivirine Therapy.
Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Published: December 14, 2024
Impact of Switching to Long-Acting Injectable Cabotegravir Plus Rilpivirine on Rectal HIV-1 RNA Shedding and Implications for Transmission Risk.
Journal: The Journal of infectious diseases
Published: July 12, 2024
Virological History Predicts Non-sustained Viral Suppression With Long-Acting Cabotegravir and Rilpivirine Therapy, Independent of Pharmacokinetic Parameters.
Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Published: July 09, 2024
Last Updated: 09/26/2026